在具有丰富治疗经验且病毒学得到抑制的HIV-1感染患者中，换用马拉维若/雷特格韦联合治疗后的病毒反弹情况。 - Suppr

Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.

作者信息

Nozza Silvia, Bigoloni Alba, Calcagno Andrea, Galli Laura, Pignataro Angela Rosa, D'Avolio Antonio, Carbone Alessia, Ripa Marco, Bonora Stefano, Lazzarin Adriano, Castagna Antonella

机构信息

San Raffaele Scientific Institute, Milan, Italy.

出版信息

J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23.

DOI:10.1093/jac/dkt530

PMID:24458511

Abstract

摘要

相似文献

Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.

J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23.

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.

Antiviral Res. 2010 May;86(2):224-6. doi: 10.1016/j.antiviral.2010.02.324. Epub 2010 Mar 6.

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.

J Antimicrob Chemother. 2014 Jun;69(6):1648-52. doi: 10.1093/jac/dkt536. Epub 2014 Feb 16.

Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1203-10. doi: 10.1089/AID.2012.0330. Epub 2013 Jun 25.

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).

J Antimicrob Chemother. 2015 Dec;70(12):3339-44. doi: 10.1093/jac/dkv280. Epub 2015 Sep 22.

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.

AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066.

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

J Med Virol. 2012 Dec;84(12):1869-75. doi: 10.1002/jmv.23409.

Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.

Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6.

Virological failure of patients on maraviroc-based antiretroviral therapy.

J Antimicrob Chemother. 2015;70(6):1858-64. doi: 10.1093/jac/dkv026. Epub 2015 Feb 19.

Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.

Curr HIV Res. 2010 Sep;8(6):482-6. doi: 10.2174/157016210793499295.

引用本文的文献

Maraviroc: a review of its use in HIV infection and beyond.

Drug Des Devel Ther. 2015 Oct 1;9:5447-68. doi: 10.2147/DDDT.S90580. eCollection 2015.

Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.

AIDS Res Hum Retroviruses. 2014 Dec;30(12):1243-50. doi: 10.1089/aid.2014.0124.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.

作者信息

Nozza Silvia, Bigoloni Alba, Calcagno Andrea, Galli Laura, Pignataro Angela Rosa, D'Avolio Antonio, Carbone Alessia, Ripa Marco, Bonora Stefano, Lazzarin Adriano, Castagna Antonella

机构信息

San Raffaele Scientific Institute, Milan, Italy.

出版信息

J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23.

DOI:10.1093/jac/dkt530

PMID:24458511

Abstract

摘要

相似文献

Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.

J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23.

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.

Antiviral Res. 2010 May;86(2):224-6. doi: 10.1016/j.antiviral.2010.02.324. Epub 2010 Mar 6.

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.

J Antimicrob Chemother. 2014 Jun;69(6):1648-52. doi: 10.1093/jac/dkt536. Epub 2014 Feb 16.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1203-10. doi: 10.1089/AID.2012.0330. Epub 2013 Jun 25.

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).

J Antimicrob Chemother. 2015 Dec;70(12):3339-44. doi: 10.1093/jac/dkv280. Epub 2015 Sep 22.

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.

AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066.

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

J Med Virol. 2012 Dec;84(12):1869-75. doi: 10.1002/jmv.23409.

Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.

Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688. Epub 2010 Apr 6.

Virological failure of patients on maraviroc-based antiretroviral therapy.

J Antimicrob Chemother. 2015;70(6):1858-64. doi: 10.1093/jac/dkv026. Epub 2015 Feb 19.

Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.

Curr HIV Res. 2010 Sep;8(6):482-6. doi: 10.2174/157016210793499295.

引用本文的文献

Maraviroc: a review of its use in HIV infection and beyond.

Drug Des Devel Ther. 2015 Oct 1;9:5447-68. doi: 10.2147/DDDT.S90580. eCollection 2015.

Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.

AIDS Res Hum Retroviruses. 2014 Dec;30(12):1243-50. doi: 10.1089/aid.2014.0124.

Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.

作者信息

机构信息

出版信息

相似文献

引用本文的文献